News

India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...
Participants were randomly assigned to receive either dapagliflozin 10 mg daily or placebo for 12 months. Patients were ...
Combination therapy of insulin and dapagliflozin improved kidney function and blood sugar in teens with T1D * The study focused on adolescents, an age group often underrepresented in //clinical trials ...
On 21 July 2025, the Court of Appeal delivered a significant ruling in AstraZeneca AB & Anor v Generics (UK) Limited & Ors, ...
Combining insulin treatment with the investigational drug dapagliflozin may improve health outcomes for adolescents with type ...
Dapagliflozin, sold as Farxiga by AstraZeneca, received an indication from FDA in October to reduce the risk of hospitalization for HF for patients with type 2 diabetes and established CV ...
The judgement, delivered on 16 July 2025, upheld the High Court's April 2025 ruling that declared AstraZeneca's dapagliflozin patent invalid for lack of inventive step and insufficiency. The central ...
Dapagliflozin reduced the total number of events, first and recurrent (337 vs 442 among the population of 17,160 patients), for an incidence rate ratio of 0.77 (95% CI, 0.64-0.92; P = .005).
Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ...
Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...
Dapagliflozin reduces the risk for hospitalization among patients with nondialysis-dependent chronic kidney disease, a new analysis confirms. In a post hoc analysis of the DAPA-CKD (Dapagliflozin ...
Among patients hospitalized with COVID-19, dapagliflozin was well tolerated and did not increase risk of AKI in patients, according to data published in the Clinical Journal of the American ...